Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03GET
|
|||
| Former ID |
DAP000544
|
|||
| Drug Name |
Menadione
|
|||
| Synonyms |
menadione; 58-27-5; Vitamin K3; 2-Methyl-1,4-naphthoquinone; Menaphthone; 2-methylnaphthalene-1,4-dione; 2-Methylnaphthoquinone; Thyloquinone; Panosine; Klottone; Kayquinone; Kappaxin; Kayklot; Kolklot; 2-Methyl-1,4-naphthalenedione; Menaphthon; Menadion; Kipca; Kanone; Mitenone; Kativ-G; Kaergona; Aquinone; Prokayvit; Mitenon; Koaxin; Kaykot; Kareon; Hemodal; Aquakay; Synkay; Karcon; K-Thrombyl; K-Vitan; Kipca-Oil Soluble; Juva-K; Vitamin K2(0); Vitamin K0; Menaquinone 0; Vitamin K 3; Menaphtone; Menadionum; 2-Methyl-1,4-naphthochinon; Usaf; Aquakay; Klottone;Koaxin; Memodol; Methylnaphthoquinone; Vicasol; Menadione semiquinone; M0373; VK3; Kappaxan (VAN); Kappaxin (TN); Kipca, oil soluble; Menadione (K3); Menadione (USP); Menadione [USAN:BAN]; Usaf ek-5185; Vitamin-K3; Methyl-1,4-naphthalenedione; Methyl-1,4-naphthoquinone; Vitamin K3 : 2-Methyl-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-,radical ion(1-); 2-Methyl-1,4-naftochinon; 2-Methyl-1,4-naftochinon [Czech]; 2-Methyl-1,4-naphthochinon [German]; 2-methyl-1,4-naphthoquinone, 5; 3-Methyl-1,4-naphthoquinone; Ascorbic acid/menadione; Triglycyl-lysine-vasopressin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Vitamin K deficiency [ICD-11: 5B59; ICD-10: E56, E56.1; ICD-9: 269] | Approved | [1] | |
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [2] | ||
| Therapeutic Class |
Vitamins
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H8O2
|
|||
| Canonical SMILES |
CC1=CC(=O)C2=CC=CC=C2C1=O
|
|||
| InChI |
1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3
|
|||
| InChIKey |
MJVAVZPDRWSRRC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 58-27-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7751, 70547, 607330, 853737, 853809, 3133921, 6380040, 7849394, 7891061, 8136904, 8149919, 8152543, 10321386, 10528213, 11112142, 11120351, 11120839, 11121327, 11335255, 11341462, 11360494, 11361645, 11364122, 11364936, 11366684, 11367498, 11369246, 11370060, 11373099, 11374123, 11375660, 11377408, 11378230, 11408337, 11446754, 11461466, 11466487, 11467607, 11485003, 11486213, 11487047, 11489010, 11492537, 11495042, 11532917, 11533196, 12016111, 14772598, 22389508, 24871411
|
|||
| ChEBI ID |
CHEBI:28869
|
|||
| SuperDrug ATC ID |
B02BA02
|
|||
| SuperDrug CAS ID |
cas=000058275
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli Nissle 1917
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Metabolic Effect | Decrease activity | |||
| Description | Menadione can be metabolized by Escherichia coli Nissle 1917, which results in the decrease of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aldehyde oxidase (AOX1) | Target Info | Inhibitor | [4], [5] |
| Vasopressin V1 receptor (V1R) | Target Info | Agonist | [6] | |
| BioCyc | Nicotine degradation III | |||
| Nicotine degradation IV | ||||
| KEGG Pathway | Valine, leucine and isoleucine degradation | |||
| Tyrosine metabolism | ||||
| Tryptophan metabolism | ||||
| Vitamin B6 metabolism | ||||
| Nicotinate and nicotinamide metabolism | ||||
| Retinol metabolism | ||||
| Drug metabolism - cytochrome P450 | ||||
| Metabolic pathways | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Pathwhiz Pathway | Valine, Leucine and Isoleucine Degradation | |||
| Vitamin B6 Metabolism | ||||
| Nicotinate and Nicotinamide Metabolism | ||||
| Tryptophan Metabolism | ||||
| WikiPathways | Tryptophan metabolism | |||
| Effects of Nitric Oxide | ||||
| Metabolism of water-soluble vitamins and cofactors | ||||
| Nicotine Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 002139. | |||
| REF 2 | ClinicalTrials.gov (NCT01272830) Double-Blinded Clinical Trial Using ApatoneB for Symptomatic Postoperative Total Joint Replacements. U.S. National Institutes of Health. | |||
| REF 3 | Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015 Sep 29;5:14554. | |||
| REF 4 | Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochem Pharmacol. 1993 May 25;45(10):2159-62. | |||
| REF 5 | Cytosol mediated metabolism of the experimental antitumor agent acridine carboxamide to the 9-acridone derivative. Biochem Pharmacol. 1991 Oct 24;42(10):1879-84. | |||
| REF 6 | Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol. 1996 May;7(5):805-10. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.